The genetically defined myelodysplastic syndromes in the ICC guidelines are several, similar to the WHO, and include the following: MDS with mutated SF3B1 (MDS-SF3B1); MDS with del(5q)[MDS-del(5q)]; MDS, NOS without dysplasia (defined by the presence of at least one cytopenia and -7/del(7q) or complex cytogenetics and/or any MDS-associated mutations with a variant allele frequency of at least 10%, excluding multi-hit TP53 or SF3B1); and MDS with mutated TP53. This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.